Dynavax (DVAX) Revenue & Revenue Breakdown
Dynavax Revenue Highlights
Latest Revenue (Y)
$232.28M
Latest Revenue (Q)
$73.80M
Main Segment (Y)
Product
Main Geography (Y)
UNITED STATES
Dynavax Revenue by Period
Dynavax Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $232.28M | -67.86% |
| 2022-12-31 | $722.68M | 64.45% |
| 2021-12-31 | $439.44M | 844.00% |
| 2020-12-31 | $46.55M | 32.18% |
| 2019-12-31 | $35.22M | 329.60% |
| 2018-12-31 | $8.20M | 2407.03% |
| 2017-12-31 | $327.00K | -97.04% |
| 2016-12-31 | $11.04M | 172.67% |
| 2015-12-31 | $4.05M | -63.29% |
| 2014-12-31 | $11.03M | -1.95% |
| 2013-12-31 | $11.25M | 15.82% |
| 2012-12-31 | $9.71M | -55.06% |
| 2011-12-31 | $21.61M | -9.75% |
| 2010-12-31 | $23.95M | -40.60% |
| 2009-12-31 | $40.32M | 8.69% |
| 2008-12-31 | $37.09M | 163.21% |
| 2007-12-31 | $14.09M | 190.76% |
| 2006-12-31 | $4.85M | -66.93% |
| 2005-12-31 | $14.65M | -1.06% |
| 2004-12-31 | $14.81M | 1693.22% |
| 2003-12-31 | $826.00K | -42.12% |
| 2002-12-31 | $1.43M | -39.51% |
| 2001-12-31 | $2.36M | 100.00% |
| 2000-12-31 | - | - |
Dynavax generated $232.28M in revenue during NA 2023, up -67.86% compared to the previous quarter, and up 2833.42% compared to the same period a year ago.
Dynavax Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $73.80M | 45.29% |
| 2024-03-31 | $50.79M | -8.64% |
| 2023-12-31 | $55.60M | -20.02% |
| 2023-09-30 | $69.51M | 15.38% |
| 2023-06-30 | $60.25M | 28.39% |
| 2023-03-31 | $46.92M | -74.57% |
| 2022-12-31 | $184.49M | 9.99% |
| 2022-09-30 | $167.74M | -34.60% |
| 2022-06-30 | $256.46M | 124.98% |
| 2022-03-31 | $113.99M | -41.56% |
| 2021-12-31 | $195.07M | 80.17% |
| 2021-09-30 | $108.27M | 105.19% |
| 2021-06-30 | $52.77M | -36.68% |
| 2021-03-31 | $83.33M | 326.27% |
| 2020-12-31 | $19.55M | 45.74% |
| 2020-09-30 | $13.41M | 402.77% |
| 2020-06-30 | $2.67M | -75.57% |
| 2020-03-31 | $10.92M | 3.30% |
| 2019-12-31 | $10.57M | -0.05% |
| 2019-09-30 | $10.57M | 27.39% |
| 2019-06-30 | $8.30M | 43.79% |
| 2019-03-31 | $5.77M | 8.56% |
| 2018-12-31 | $5.32M | 264.00% |
| 2018-09-30 | $1.46M | 16.51% |
| 2018-06-30 | $1.25M | 660.00% |
| 2018-03-31 | $165.00K | 685.71% |
| 2017-12-31 | $21.00K | -60.38% |
| 2017-09-30 | $53.00K | -49.52% |
| 2017-06-30 | $105.00K | -29.05% |
| 2017-03-31 | $148.00K | -97.97% |
| 2016-12-31 | $7.29M | 4401.23% |
| 2016-09-30 | $162.00K | -93.88% |
| 2016-06-30 | $2.65M | 181.00% |
| 2016-03-31 | $942.00K | 37.52% |
| 2015-12-31 | $685.00K | -42.34% |
| 2015-09-30 | $1.19M | -23.35% |
| 2015-06-30 | $1.55M | 147.21% |
| 2015-03-31 | $627.00K | -72.46% |
| 2014-12-31 | $2.28M | 3.08% |
| 2014-09-30 | $2.21M | -27.53% |
| 2014-06-30 | $3.05M | -12.86% |
| 2014-03-31 | $3.50M | 22.87% |
| 2013-12-31 | $2.85M | -2.73% |
| 2013-09-30 | $2.93M | -13.71% |
| 2013-06-30 | $3.39M | 62.69% |
| 2013-03-31 | $2.08M | 15.45% |
| 2012-12-31 | $1.81M | -37.16% |
| 2012-09-30 | $2.87M | 7.08% |
| 2012-06-30 | $2.68M | 14.21% |
| 2012-03-31 | $2.35M | -79.43% |
| 2011-12-31 | $11.43M | 873.34% |
| 2011-09-30 | $1.17M | -83.85% |
| 2011-06-30 | $7.27M | 316.80% |
| 2011-03-31 | $1.74M | -1.25% |
| 2010-12-31 | $1.77M | -84.84% |
| 2010-09-30 | $11.65M | 431.68% |
| 2010-06-30 | $2.19M | -73.74% |
| 2010-03-31 | $8.34M | 281.18% |
| 2009-12-31 | $2.19M | -24.54% |
| 2009-09-30 | $2.90M | -81.74% |
| 2009-06-30 | $15.88M | -17.89% |
| 2009-03-31 | $19.34M | 61.94% |
| 2008-12-31 | $11.95M | 34.87% |
| 2008-09-30 | $8.86M | -11.23% |
| 2008-06-30 | $9.98M | 58.03% |
| 2008-03-31 | $6.31M | -32.07% |
| 2007-12-31 | $9.29M | - |
Dynavax generated $73.80M in revenue during Q2 2024, up 45.29% compared to the previous quarter, and up 157.26% compared to the same period a year ago.
Dynavax Revenue Breakdown
Dynavax Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 21 | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|---|---|
| Cp G1018 | - | $38.21M | $3.28M | - | - |
| Other Revenue | $18.99M | $432.00K | - | - | - |
| Product | $213.29M | $39.31M | $34.64M | $6.81M | - |
| H E P L I S A V B | $213.29M | $800.00K | - | - | - |
| Collaboration Revenue | - | - | - | $143.00K | $1.39M |
Dynavax's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (47.87%), H E P L I S A V B (47.87%), and Other Revenue (4.26%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $47.84M | $150.98M | $62.32M | $82.89M | $13.11M | $13.28M | $2.40M | $10.51M | $10.56M | $10.16M | $8.30M | $5.63M | $3.93M | $1.46M | - | - | - | - | - | - |
| H E P L I S A V B | $47.84M | $150.98M | $62.32M | $700.00K | $11.51M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Revenue | $2.94M | $11.79M | $7.20M | $263.00K | $405.00K | $-131.00K | $417.00K | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Cp G1018 | - | - | - | $87.04M | $99.07M | $126.37M | $37.03M | $1.16M | $37.05M | $74.58M | $1.60M | - | - | - | - | - | - | - | - | - |
| Coalition For Epidemic Preparedness Innovations | - | - | - | - | - | - | $400.00K | $68.00M | $107.00M | - | - | - | - | - | - | - | - | - | - | - |
| Collaboration Revenue | - | - | - | - | - | - | - | - | - | - | - | $100.00K | $146.00K | - | - | - | - | - | - | - |
Dynavax's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Product (48.51%), H E P L I S A V B (48.51%), and Other Revenue (2.99%).
Dynavax Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|
| UNITED STATES | $230.94M | $8.77M | $1.92M |
| Non-US | $1.34M | $588.65M | $428.00K |
Dynavax's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (99.42%), and Non-US (0.58%).
Quarterly Revenue by Country
| Country | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-US | $1.29M | - | - | - | $147.24M | $126.31M | $223.58M | $59.00K | $74.00K | - | - | - |
| UNITED STATES | $49.50M | $154.15M | $69.51M | $3.81M | $3.47M | $2.21M | $3.88M | $1.08M | $1.61M | $455.00K | $23.91M | $260.00K |
| Non Us | - | - | - | - | - | - | - | - | - | - | $84.36M | $39.08M |
Dynavax's latest quarterly revenue breakdown by geography, as of Mar 24: UNITED STATES (97.46%), and Non-US (2.54%).
Dynavax Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| NBIX | Neurocrine Biosciences | $1.89B | $590.20M |
| ALKS | Alkermes | $1.66B | $399.13M |
| LNTH | Lantheus | $1.30B | $394.09M |
| EBS | Emergent BioSolutions | $1.05B | $254.70M |
| PCRX | Pacira BioSciences | $674.98M | $178.02M |
| AMPH | Amphastar Pharmaceuticals | $593.24M | $182.39M |
| COLL | Collegium Pharmaceutical | $566.77M | $144.92M |
| ANIP | ANI Pharmaceuticals | $486.82M | $138.04M |
| ITCI | Intra-Cellular Therapies | $462.18M | $144.87M |
| IRWD | Ironwood Pharmaceuticals | $442.74M | $94.40M |
| EGRX | Eagle Pharmaceuticals | $316.61M | $64.65M |
| DVAX | Dynavax | $232.28M | $73.80M |
| DCPH | Deciphera Pharmaceuticals | $163.36M | $45.00M |
| AQST | Aquestive Therapeutics | $50.58M | $20.10M |
| DRRX | DURECT | $8.55M | $1.83M |
DVAX Revenue FAQ
What is Dynavax’s yearly revenue?
Dynavax's yearly revenue for 2023 was $232.28M, representing a decrease of -67.86% compared to 2022. The company's yearly revenue for 2022 was $722.68M, representing an increase of 64.45% compared to 2021. DVAX's yearly revenue for 2021 was $439.44M, representing an increase of 844.00% compared to 2020.
What is Dynavax’s quarterly revenue?
Dynavax's quarterly revenue for Q2 2024 was $73.8M, a 45.29% increase from the previous quarter (Q1 2024), and a 22.48% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $50.79M, a -8.64% decrease from the previous quarter (Q4 2023), and a 8.24% increase year-over-year (Q1 2023). DVAX's quarterly revenue for Q4 2023 was $55.6M, a -20.02% decrease from the previous quarter (Q3 2023), and a -69.87% decrease year-over-year (Q4 2022).
What is Dynavax’s revenue growth rate?
Dynavax's revenue growth rate for the last 3 years (2021-2023) was -47.14%, and for the last 5 years (2019-2023) was 559.54%.
What are Dynavax’s revenue streams?
Dynavax's revenue streams in c 23 are Other Revenue, Product, and H E P L I S A V B. Other Revenue generated $18.99M in revenue, accounting 4.26% of the company's total revenue, up 4295.60% year-over-year. Product generated $213.3M in revenue, accounting 47.87% of the company's total revenue, up 442.64% year-over-year. H E P L I S A V B generated $213.3M in revenue, accounting 47.87% of the company's total revenue, up 26561.88% year-over-year.
What is Dynavax’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Dynavax was Product. This segment made a revenue of $213.3M, representing 47.87% of the company's total revenue.